KEYCORP TO PRESENT AT THE MORGAN STANLEY U.S. FINANCIALS CONFERENCE
CLEVELAND, June 4, 2025 /PRNewswire/ — KeyCorp (NYSE: KEY) announced today that Ken Gavrity, Head of Commercial Banking, and Clark Khayat, Chief Financial Officer, will present at the Morgan Stanley U.S. Financials Conference on Wednesday, June 11, 2025, at 1:00 p.m. ET in New York City.
KeyCorp plans to review its performance, strategy, and outlook, and the discussion may include forward-looking statements and other material information. The live audio webcast will be available on the day of the conference at www.key.com/ir. If you are unable to join the live webcast, or wish to hear a re-broadcast, access www.key.com/ir and select Events & Presentations.
ABOUT KEYCORP
In 2025, KeyCorp celebrates its bicentennial, marking 200 years of service to clients and communities from Maine to Alaska. To learn more, visit KeyBank Heritage Center. Headquartered in Cleveland, Ohio, Key is one of the nation’s largest bank-based financial services companies, with assets of approximately $189 billion at March 31, 2025.
Key provides deposit, lending, cash management, and investment services to individuals and businesses in 15 states under the name KeyBank National Association through a network of approximately 1,000 branches and approximately 1,200 ATMs. Key also provides a broad range of sophisticated corporate and investment banking products, such as merger and acquisition advice, public and private debt and equity, syndications and derivatives to middle market companies in selected industries throughout the United States under the KeyBanc Capital Markets trade name. For more information, visit https://www.key.com/. KeyBank Member FDIC.
SOURCE KeyCorp
WANT YOUR COMPANY’S NEWS FEATURED ON PRNEWSWIRE.COM?

Newsrooms &
Influencers

Digital Media
Outlets

Journalists
Opted In
Related news for (KEY)
- AUKEY Unveils MagFusion Ark, the World’s First Modular True Wireless Charger, at IFA 2025
- KEYCORP TO PRESENT AT THE BARCLAYS GLOBAL FINANCIAL SERVICES CONFERENCE
- IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed
- StrategX Elements Corp Provides Overview of Melville Region and Key Objectives for Nagvaak Project
- KEYCORP REPORTS SECOND QUARTER 2025 NET INCOME OF $387 MILLION, OR $.35 PER DILUTED COMMON SHARE